← All diseases

Neuromuscular diseases

Aicardi-Goutières syndrome (AGS)

An inherited disease that affects the brain, the immune system and the skin. It usually begins in infancy. Brain development is affected.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

This page is translated from the Turkish original.

This disease is followed through the “Neuromuscular diseases” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

The cells cannot clear away pieces of DNA and RNA that are no longer useful. The body mistakes them for viruses. The immune system works when it does not need to, and substances called interferons increase. This inflammation damages the brain, the skin and other organs.

Which symptoms can occur?

In the early type, symptoms begin in the first months. In the late type, the baby first develops normally, and symptoms appear after the age of one.

  • Extreme irritability and feeding difficulties
  • Loss of skills already gained
  • Recurring fever without infection
  • Seizures, also called fits (sometimes)
  • Slowed growth of the head
  • Muscle stiffness, involuntary muscle contractions or floppy muscles
  • Red, itchy swellings on the fingers, nose and ears that get worse in the cold (about 40% in the early type)
  • Raised eye pressure and vision problems (sometimes)

How is it diagnosed?

A brain CT scan shows calcium deposits, and an MRI shows changes in the white matter. White blood cells and interferon may be increased in the cerebrospinal fluid. The diagnosis is confirmed with a genetic test.

Treatment and care

There is not yet a treatment that fully cures the disease. Many specialists work together on care. This includes nutritional support, chest physiotherapy and treatment of seizures. Medicines that suppress the immune response are being researched. The eyes, thyroid and spine are checked regularly. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

It is usually passed on through recessive inheritance. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Recessive diseases can be more common when relatives marry each other. With some genes, dominant inheritance or a new gene change is also seen. Genetic counselling clarifies the family's risk.

Source: MedlinePlus Genetics: Aicardi-Goutières syndrome · GeneReviews: Aicardi-Goutières Syndrome · NORD: Aicardi-Goutières Syndrome

Key facts

How common is it?
Prevalence: 1-5 per 10 000 (Europe)
When does it usually start?
Before birth, Infancy, Newborn period
Gene(s) involved
RNASEH2A, RNASEH2B, RNASEH2C, ADAR, TREX1, SAMHD1

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

We could not find a patient association specific to this disease.

For all rare diseases: Nadir Hastalıklar Federasyonu

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about Aicardi-Goutières

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.

See all studies on ClinicalTrials.gov · Joining clinical trials

Neuromuscular diseases: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:51

No separate ICD-11 code; WHO classifies this disease under: 5C55.2

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.